Vocinti 10 mg Film-Coated Tablet Philippines - English - FDA (Food And Drug Administration)

vocinti 10 mg film-coated tablet

japan; importer: n/a; distributor: takeda healthcare philippines, inc. - vonoprazan (as fumarate) - film-coated tablet - 10 mg

Vocinti 20 mg Film-Coated Tablet Philippines - English - FDA (Food And Drug Administration)

vocinti 20 mg film-coated tablet

japan; importer: n/a; distributor: takeda healthcare philippines, inc. - vonoprazan (as fumarate) - film-coated tablet - 20 mg

IMOJEV japanese encephalitis vaccine (live, attenuated) powder for injection vial plus diluent vial Australia - English - Department of Health (Therapeutic Goods Administration)

imojev japanese encephalitis vaccine (live, attenuated) powder for injection vial plus diluent vial

biocelect pty ltd - japanese encephalitis virus, quantity: 4 pfu - injection, powder for - excipient ingredients: albumin; mannitol; glutamic acid; histidine; sodium chloride; potassium hydroxide; lactose monohydrate; water for injections - imojev is indicated for prophylaxis of japanese encephalitis caused by the japanese encephalitis virus, in individuals from 9 months of age and over.

JESPECT Japanese encephalitis virus purified inactivated vaccine 0.5mL suspension for injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

jespect japanese encephalitis virus purified inactivated vaccine 0.5ml suspension for injection syringe

seqirus pty ltd - japanese encephalitis virus, quantity: 6 agu - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate; water for injections - jespect is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect is indicated for persons who work with je virus in laboratories and in industry.

Nisseiken Japanese Encephalitis TC Vaccine Inactivated New Zealand - English - Ministry for Primary Industries

nisseiken japanese encephalitis tc vaccine inactivated

new zealand bloodstock ltd - japanese encephalitis virus - japanese encephalitis virus 0 vaccine - vaccine

Entyvio 300 mg Powder for Concentrate for Solution for  Infusion (IV) Philippines - English - FDA (Food And Drug Administration)

entyvio 300 mg powder for concentrate for solution for infusion (iv)

takeda pharma a/s; importer: takeda healthcare philippines inc.; distributor: n/a - vedolizumab - powder for concentrate for solution for infusion (iv) - 300 mg

Blopress 16 mg Tablet Philippines - English - FDA (Food And Drug Administration)

blopress 16 mg tablet

n/a; importer: celltrion healthcare philippines, inc.; distributor: n/a - candesartan cilexetil - tablet - 16 mg

Ixiaro European Union - English - EMA (European Medicines Agency)

ixiaro

valneva austria gmbh - japanese-encephalitis virus, inactivated (attenuated strain sa14-14-2 grown in vero cells) - encephalitis, japanese; immunization - vaccines - ixiaro is indicated for active immunisation against japanese encephalitis in adults, adolescents, children and infants aged two months and older.ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

IXIARO- japanese encephalitis vaccine, inactivated, adsorbed injection, suspension United States - English - NLM (National Library of Medicine)

ixiaro- japanese encephalitis vaccine, inactivated, adsorbed injection, suspension

valneva scotland ltd. - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml - ixiaro is a vaccine indicated for the prevention of disease caused by japanese encephalitis virus (jev). ixiaro is approved for use in individuals 2 months of age and older. severe allergic reaction (e.g., anaphylaxis) after a previous dose of ixiaro, any other japanese encephalitis virus vaccine, or any component of ixiaro, including protamine sulfate, is a contraindication to administration of ixiaro [see description (11)]. alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with ixiaro is considered. pregnancy category b. reproduction studies have been performed in female rats at doses approximately 300-fold excess relative to the projected human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to ixiaro. there are, however, no adequate and well‑controlled